Use of quetiapine in child and adolescent populations – Response to letter from Dr Lambe

Australian & New Zealand Journal of Psychiatry, 47(11) Gentile S and Galbally M (2010) Prenatal exposure to antidepressant medications and neurodevelopmental outcomes: A systematic review. Journal of Affective Disorders 128: 1–9. Grigoriadis S, Vonderporten EH, Mamisashvili L, et al. (2013) Antidepressant exposure during pregnancy and congenital malformations: is there an association? a systematic review and meta-analysis of the best evidence. Journal of Clinical Psychiatry 74: e293–e308. Lewis A, Galbally M and Bailey C (2012) Perinatal mental health, antidepressants and neonatal outcomes: Findings from the Longitudinal Study of Australian Children. Neonatal, Paediatric and Child Health Nursing 15: 22–28. Malm H, Artama M, Gissler M, et al. (2011) Selective serotonin reuptake inhibitors and risk for major congenital anomalies. Obstetrics & Gynecology 118: 111–120. Myles N, Newall H, Ward H and Large M (2013) Systematic meta-analysis of individual selective serotonin reuptake inhibitor medications and congenital malformations. Australian and New Zealand Journal of Psychiatry 47: 1001–1011. O’Brien L, Einarson TR, Sarkar M, et al. (2008) Does paroxetine cause cardiac malformations? Journal of Obstetrics and Gynaecology Canada 30: 696–701. Rahimi R, Nikfar S and Abdollahi M (2006) Pregnancy outcomes following exposure to serotonin reuptake inhibitors: A meta-analysis of clinical trials. Reproductive Toxicology 22: 571–575. Wurst KE, Poole C, Ephross SA, et al. (2010) First trimester paroxetine use and the prevalence of congenital, specifically cardiac, defects: A meta-analysis of epidemiological studies. Birth Defects Research. Part A, Clinical and Molecular Teratology 88: 159–170.